Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2013

Bauer Robert C, Sänger Jana, Peschel Christian, Duyster Justus, von Bubnoff Nikolas

Abstract excerpt

PURPOSE: Dasatinib and nilotinib are active in imatinib-resistant chronic myelocytic leukemia (CML) and many patients undergo sequential treatment. We aimed at modeling sequential tyrosine kinase inhibitor (TKI) resistance in vitro to compare the sequences imatinib-nilotinib-dasatinib and imatinib-dasatinib-nilotinib. EXPERIMENTAL DESIGN: We designed an in vitro model for sequential TKI resistance in CML....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 23549879
DOI: 10.1158/1078-0432.CCR-13-0052

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.PMID 23549879Read ↗

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patientsSemantic proximity Read ↗

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?Semantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.Semantic proximity Read ↗

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Semantic proximity Read ↗

New directions in the treatment of imatinib failure and/or resistance.Semantic proximity Read ↗

Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.Semantic proximity Read ↗

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemiaSemantic proximity Read ↗

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.